Institutional financing supports continued execution of late-stage program evaluating JURVIGO® (udenafil) in patients living with Fontan circulation

机构融资支持对生活在Fontan循环中的患者进行JURVIGO®（udenafil）晚期阶段项目的持续执行评估。

FORT LEE, N.J.

纽约州李堡

,

，

May 14, 2026

2026年5月14日

/PRNewswire/ -- Mezzion Pharmaceuticals, Inc., a late-stage rare disease biopharmaceutical company focused on therapies for patients with single ventricle congenital heart disease and Fontan circulation, today announced the successful completion of strategic financing from institutional investors.

/PRNewswire/ -- 专注于单心室先天性心脏病和Fontan循环患者治疗的晚期罕见病生物制药公司Mezzion Pharmaceuticals, Inc.今天宣布，已成功完成来自机构投资者的战略融资。

The financing is expected to support continued advancement of Mezzion's ongoing global confirmatory Phase 3 FUEL-2 clinical trial evaluating udenafil in adolescents and young adults living with Fontan circulation, a serious and life-limiting form of congenital heart disease for which there are currently no approved therapies specifically indicated for Fontan patients..

这笔融资预计将支持Mezzion公司正在进行的全球关键性三期临床试验FUEL-2的持续推进，该试验评估乌地那非在法洛四联症循环的青少年和年轻成人患者中的应用。法洛四联症是一种严重且限制生命的先天性心脏病，目前尚无特别针对法洛四联症患者的获批疗法。

'This financing represents an important step in supporting the continued advancement of FUEL-2 and our commitment to the Fontan community,' said Dr. Ridwan Shabsigh, President and COO of Mezzion Pharmaceuticals. 'We remain focused on executing the study with the goal of potentially bringing the first approved therapy specifically indicated for individuals with Fontan physiology.'.

“这笔融资代表了支持FUEL-2持续进展以及我们对Fontan患者群体承诺的重要一步，”Mezzion制药公司总裁兼首席运营官Ridwan Shabsigh博士表示，“我们仍然专注于执行这项研究，目标是为Fontan生理患者带来首个获批的特定疗法。”

The financing follows the continued enrollment momentum and operational progress in the global FUEL-2 program, which is being conducted across leading pediatric congenital heart centers internationally.

融资紧随全球FUEL-2计划的持续注册势头和运营进展，该计划正在国际上领先的儿科先天性心脏中心进行。

'Despite a challenging biotech financing environment, we are grateful for the support and confidence of the institutional investors participating in this financing,' said Dean Park, Chairman and CEO of Mezzion Pharmaceuticals. 'We believe this support reflects the significant unmet medical need in patients with Fontan physiology and the potential for udenafil to meaningfully impact this underserved community.'.

“尽管生物技术融资环境充满挑战，我们仍对参与此次融资的机构投资者的支持和信心表示感谢，”美森制药董事长兼首席执行官朴振宇表示。“我们认为，这一支持反映了患有Fontan生理学的患者存在显著未满足的医疗需求，以及udenafil有望对此服务不足的群体产生有意义的影响。”

About Mezzion Pharmaceuticals

关于Mezzion制药公司

Mezzion Pharmaceuticals, Inc., a U.S.-based subsidiary of Mezzion Pharma Co., Ltd. (KOSDAQ: 140410), is a late-stage biopharmaceutical company advancing therapies for rare and underserved diseases. Mezzion is developing JURVIGO® (udenafil) as a potential first-in-class therapy for patients with single ventricle congenital heart disease and Fontan physiology.

Mezzion Pharmaceuticals, Inc. 是 Mezzion Pharma Co., Ltd.（韩国科斯达克股票代码：140410）在美国的子公司，是一家专注于研发治疗罕见病和未满足医疗需求疾病的后期生物制药公司。Mezzion 正在开发 JURVIGO®（udenafil），作为单心室先天性心脏病和 Fontan 生理患者的潜在首创疗法。

Udenafil is investigational and has not been approved by any regulatory authority. For more information, visit .

乌地那非仍在研究中，尚未获得任何监管机构的批准。欲了解更多信息，请访问 。

www.mezzion.com

www.mezzion.com

and

和

www.FUEL2Study.com

www.FUEL2学习.com

.

。

Trademarks

商标

JURVIGO® is a registered trademark of Mezzion Pharma Co., Ltd.

JURVIGO® 是 Mezzion Pharma Co., Ltd. 的注册商标。

Media Contacts:

媒体联系人：

John Presser, EVP, CBO:

约翰·普雷瑟，执行副总裁，首席业务官：

[email protected]

电子邮件地址

Mr. Sung-Il Noh, CFO:

诺成日先生，首席财务官：

[email protected]

电子邮件地址

SOURCE Mezzion Pharmaceuticals, Inc

来源：Mezzion Pharmaceuticals, Inc

21

21

%

%

more press release views with

更多新闻发布视图与

Request a Demo

请求演示